India’s National Policy to Boost R and D in Pharma and Medical Devices (Empowering Global Healthcare)
India’s government nears the launch of a pivotal national policy aimed at fueling research, development, and innovation within the pharmaceutical and medical devices sectors, according to Union Health Minister Mansukh Mandaviya. Speaking at the G20 health ministers meeting in Gandhinagar, Mandaviya emphasized India’s healthcare vision, transitioning from volume-based approaches to a value-based leadership model. This initiative showcases India’s commitment to quality, accessibility, and affordability in healthcare, a commitment underscored during the COVID-19 pandemic.
Contact Us
Final Stages of National Policy Implementation
Union Health Minister Mansukh Mandaviya announced that India is on the verge of introducing a national policy focused on advancing research, development, and innovation in the pharmaceutical and medical devices sectors. This policy, which is in its concluding stages, aims to cultivate an environment conducive to innovation and progress within these critical domains.
A Healthcare Vision for the Future
Mandaviya’s address to Indian industry leaders during the G20 health ministers meeting highlighted India’s aspiration for the future of healthcare. This vision revolves around a shift from conventional volume-based practices to a forward-looking value-based leadership model, embracing innovation and efficiency.
Unwavering Commitment to Quality and Accessibility
Mandaviya reiterated India’s unwavering dedication to ensuring quality, accessibility, and affordability in healthcare. The nation’s steadfast response to the challenges of the COVID-19 pandemic underscored its commitment to providing effective healthcare solutions.
Also Read: Parliamentary Panel Recommends Decentralisation of Medical Device Approvals in India.
Global Stage: G20 Health Ministers Meeting
Mandaviya’s remarks took place on the sidelines of the G20 health ministers meeting held in Gandhinagar from August 17-19. Indian industry leaders in pharmaceuticals, G20 ministers, and delegates were present, underscoring the significance of India’s initiatives on the global healthcare landscape.
Accelerating medical device R&D in India
Consult Operon Strategist’s regulatory experts today to streamline your testing and submission roadmap
Transitioning to Value-Based Leadership
India’s transition from traditional volume-based approaches to a value-based leadership model aligns with global trends in healthcare. This paradigm shift aims to optimize healthcare delivery by emphasizing value, effectiveness, and patient outcomes.
Fostering an Innovative Environment
Recognizing the paramount importance of research and development in healthcare advancement, Mandaviya highlighted India’s strides in fostering an innovative ecosystem. This proactive approach is poised to accelerate the pace of progress within the healthcare sector.
Collaboration: The Key to Success
Mandaviya invited collaboration from nations, industry leaders, healthcare professionals, and researchers, emphasizing that collective efforts are vital to elevate the pharmaceutical and medical devices sectors to new heights.
Global Acclaim for India's Excellence
Acknowledging India’s stature as a global hub for pharmaceutical excellence, international representatives at the G20 health minister’s meeting expressed interest in collaborating with India to harness its expertise
Impactful Model: Jan Aushadhi Kendra:
India’s Jan Aushadhi Kendra initiative, providing accessible and affordable generic medicines and surgical equipment, garnered global attention. The success of this model has inspired other nations, including Indonesia, to consider its replication.
Read Next: PLI Scheme Boosts Medical Device Manufacturing in India.
A Glimpse into the Future
With the imminent introduction of the national policy, India is poised for a groundbreaking leap in healthcare innovation. Operon Strategist commends the Indian government’s proactive approach and collaborative spirit, envisioning a brighter healthcare landscape for all.
Need technical guidance for CDSCO investigational approvals or ISO 13485 QMS setup
Connect with Operon Strategist’s consulting team today
How can Operon Strategist Help You?
To turn R&D concepts into market-ready, compliant products under national innovation schemes, companies require clear technical and regulatory guidance. Operon Strategist offers turnkey consulting services to support medical device startups, academic spin-offs, and multinational manufacturers across every phase of product development:
R&D File Preparation & Design History File (DHF) Management: Structuring complete technical dossiers, Design History Files (DHF), and ISO 14971 risk management protocols via our dedicated Quality Management System (QMS) Services.
Investigational & Commercial CDSCO Registrations: Managing test license applications (Form MD-12/13), clinical trial protocols, and commercial manufacturing/import licenses via our Global Product Registration Services.
Turnkey Facility Setup & Cleanroom Engineering: Designing audit-ready manufacturing facilities, cleanrooms, and testing labs aligned with domestic standards through our BuildNext Integrated Facility Engineering.
Audit Defense & Compliance Readiness: Delivering pre-audit gap analyses and on-site support during CDSCO inspections, Notified Body reviews, and international regulatory audits.
FAQ's
What is India's National Policy to Boost R&D in Medical Devices?
It is a government strategy designed to transition the Indian MedTech and pharma sectors from volume-based production to innovation-driven growth by expanding R&D funding, infrastructure, and industry-academia collaborations.
What is the PRIP scheme for medical devices in India?
The Promotion of Research and Innovation in Pharma-MedTech (PRIP) scheme provides ₹5,000 crore in financial assistance to foster research, prototype development, and clinical trials for innovative medical devices and drugs.
How does the R&D policy support medical device startups?
The policy provides financial grants under schemes like PRIP, simplifies regulatory testing pathways with CDSCO, and provides access to government-backed research parks.
Why is value-based healthcare important for medical device manufacturing?
Value-based healthcare shifts focus from low-cost manufacturing to product efficacy, safety, and long-term patient outcomes, encouraging companies to invest in patented, high-tech medical products
How does Operon Strategist help companies leveraging R&D incentives in India?
Operon Strategist assists MedTech companies with ISO 13485 QMS implementation, Design History File (DHF) preparation, CDSCO test license approvals, design transfer validation, and turnkey facility setup.